Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Winqvist M, Andersson PO, Asklid A, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Rosenquist R, Späth F, Hansson L, Österborg A; Swedish CLL Group.

Haematologica. 2019 May;104(5):e208-e210. doi: 10.3324/haematol.2018.198820. Epub 2018 Dec 4. No abstract available.

2.

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.

Winqvist M, Palma M, Heimersson K, Mellstedt H, Österborg A, Lundin J.

Br J Haematol. 2018 Aug;182(4):590-594. doi: 10.1111/bjh.14836. Epub 2017 Jul 5. No abstract available.

PMID:
28677818
3.

Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013.

Asklid A, Winqvist M, Eketorp Sylvan S, Mattsson A, Björgvinsson E, Søltoft F, Repits J, Diels J, Österborg A, Hansson L.

Leuk Lymphoma. 2017 May;58(5):1219-1223. doi: 10.1080/10428194.2016.1246727. Epub 2016 Nov 28. No abstract available.

PMID:
27894205
4.

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Winqvist M, Mozaffari F, Palma M, Eketorp Sylvan S, Hansson L, Mellstedt H, Österborg A, Lundin J.

Cancer Immunol Immunother. 2017 Jan;66(1):91-102. doi: 10.1007/s00262-016-1922-6. Epub 2016 Nov 4.

5.

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, Lundin J, Mattsson M, Norin S, Sandstedt A, Hansson L, Österborg A.

Haematologica. 2016 Dec;101(12):1573-1580. Epub 2016 May 19.

6.

Retinyl palmitate is a reproducible marker for chylomicron elimination from blood.

Bitzén U, Winqvist M, Nilsson-Ehle P, Fex G.

Scand J Clin Lab Invest. 1994 Dec;54(8):611-3.

PMID:
7709163

Supplemental Content

Loading ...
Support Center